Kyverna Therapeutics, Inc. (KYTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 7.12 |
| Open | 7.17 |
| Day High | 7.59 |
| Day Low | 7.13 |
| 52-Week High | 13.67 |
| 52-Week Low | 5.3 |
| Volume | 836,544 |
| Average Volume | 986,012 |
| Market Cap | 456.57M |
| PE | -2.55 |
| EPS | -2.94 |
| Moving Average 50 Days | 7.84 |
| Moving Average 200 Days | 8.42 |
| Change | 0.39 |
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
GlobeNewswire Inc.
Mar 05, 2026 9:21 PM GMT
Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG) EMERYVILLE, Calif., March 05, 2026
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced that company management wi
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support Kyverna’s next phase of growth